KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short-Term Debt issuances (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Short-Term Debt issuances for 17 consecutive years, with -$71.0 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt issuances fell 373.08% to -$71.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$115.0 million through Dec 2025, down 15.0% year-over-year, with the annual reading at -$115.0 million for FY2025, 15.0% down from the prior year.
  • Short-Term Debt issuances hit -$71.0 million in Q4 2025 for Abbott Laboratories, down from $8.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $111.0 million in Q4 2023 to a low of -$197.0 million in Q4 2021.
  • Historically, Short-Term Debt issuances has averaged -$17.6 million across 5 years, with a median of $500000.0 in 2021.
  • Biggest five-year swings in Short-Term Debt issuances: tumbled 19600.0% in 2021 and later soared 1010.0% in 2023.
  • Year by year, Short-Term Debt issuances stood at -$197.0 million in 2021, then skyrocketed by 105.08% to $10.0 million in 2022, then skyrocketed by 1010.0% to $111.0 million in 2023, then plummeted by 76.58% to $26.0 million in 2024, then tumbled by 373.08% to -$71.0 million in 2025.
  • Business Quant data shows Short-Term Debt issuances for ABT at -$71.0 million in Q4 2025, $8.0 million in Q3 2025, and -$16.0 million in Q2 2025.